Bioimaging market research report

499
-1

Published on

Bio imaging Market report focuses on the different types and modalities of bioimaging and their application in Research and Development and Diagnostics. The study provides global market analysis for bioimaging by Modalities including Ultrasound, CT, MRI, PET, SPECT and other modalities comprising X-Ray, TEM and OCT. The study includes estimations and predictions for the total global bioimaging market. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents and Research related to Bioimaging is also provided. A global perspective is presented along with regional analysis covering North America, Europe, Asia-Pacific, Latin America, and Rest of World with 146 exclusive graphically represented exhibits.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
499
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
12
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Bioimaging market research report

  1. 1. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 1 BIOIMAGING MARKET SIZE Scope of the Study Bioimaging report covers Applications and the various modalities of Bioimaging for the global market. The Applications of Bioimaging include Diagnostics and Research and Development. The report provides an in depth analysis of each of the applications and modalities by their respective categories. The study includes estimates and projections for the total global Bioimaging market and also key regional markets that include North America, Europe, Japan, Asia-Pacific (excluding Japan) and Rest of World. Estimates and projections are illustrated graphically. Business profiles of 38 major companies are discussed in the report. The report serves as a guide to global Bioimaging industry, covering 249 companies that are engaged in the development and supply of Bioimaging modalities. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report. Bioimaging report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in –  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets Analytics and data presented in this report pertain to several parameters such as –  Global and Regional Market Sizes, Market Shares, Market Trends  Product (Global and Regional) Market Sizes, Market Shares, Market Trends  Technology Trends  Corporate Intelligence  Key Companies By Sales, Brands, Products  Consumer Behavioral Patterns  Other Strategic Business Affecting Data
  2. 2. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 2 Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines – global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future. This report is uniquely researched and the methodology includes:  Need and Scope of Study  Product Definitions  Segmental Analysis  Regional Analysis  Exclusive Data Analytics  Corporate Intelligence  Feedback Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.
  3. 3. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 3 II. REPORT SYNOPSIS Bioimaging Bioimaging is a branch of science that helps in visualizing the cellular and molecular processes in real time with the help of advanced microscopic instruments (e.g. confocal laser scanning microscopes), tracers (e.g. specific fluorochromes), and imaging techniques like X-rays, magnetic resonance, positrons, electrons, ultrasound, light and fluorescence. The images are used for data collection in respect to various aspects of these processes such as quantities of ions and molecular movements. The data collected in the above manner is used for estimating metabolic activity rates and other inter and intra cellular exchanges, anatomical functions, etc., by applying the principles of physics, biology, chemistry and engineering. The estimates are then extrapolated and analyzed through non-imaging means for gaining knowledge of physiological and biological processes and events, including pathways of diseases and therapies. Therefore, bioimaging entails the use of above methods for understanding  Intra and inter cell processes;  Molecular reactions; and  Response to a drug or chemicals without using any surgical or other invasive methods. Unlike other procedures, bioimaging does not disturb the process. Therefore, the pathogens or cells continue to function, leaving no process or part thereof, open for conjecture. Bioimaging sheds light on the molecular interactions, and levels of such interactions. It has become an important source of information for proteomics, genomics, and other branches of bioinformatics. Quite often, bioimaging is used to develop a three-dimensional model of the biological material. Such models help in designing drugs to attack a specific bond or reaction. Bioimaging could be broadly classified into two categories, which are:  Medical imaging – generally related to healthcare sector functions;  Molecular imaging - generally related to research. Medical Imaging Medical imaging is a branch of bioimaging that entails imaging the movement of medicines or drugs in the human body, or imaging part of the human body with the help of technologies such as X-ray, CT or PET-CT. It gives an insight into the working of human or animal body, and its biological functions, and cellular processes etc., without the need to resort to surgery, or other invasive methods. Medical imaging implies development of an image of the body or part thereof that has the disease and studying this image of the anatomy vis-à-vis its function in the body. Radiology, endoscopy, thermography, microscopy, radiological sciences, and medical photography, are the normally used biomedical imaging
  4. 4. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 4 techniques. In addition, techniques such as electroencephalography (EEG) and magnetoencephalography (MEG), which do not generate images, but generate data that could be read as maps for analyzing the abnormal variations in measurements of some process also, form part of biomedical imaging. Radiology is now a standard clinical imaging procedure. Diagnostic radiography refers to medical imaging of a certain body part with an object to generate technical data that is expected to exhibit some variations from normal in case of any disease or injury. The medical practitioner deciphering the images generated through radiological imaging is better known as radiologist. Radiographer or radiological technologist on the other hand is a person who collects the biomedical images (diagnostic radiographical images), for facilitating diagnosis. Radiologists, at times, direct the radiographer for the required information. Other than X-ray imaging, there are many modern biomedical-imaging methods that have unique abilities. For example:  Fluorescence imaging  Ultrasound imaging  Positron emission tomography (PET)  Single photon emission coherence tomography (SPECT)  Magnetic resonance imaging (MRI)  Computed (x-ray) tomography  Optical coherence tomography (OCT) Physicians and medical practitioners use the images generated by such techniques to assess the extent of damage caused by any injury or progress of any disease. This helps them in deciding the strategic course of action, which may entail treatment with drugs or surgery. By using molecular agents along with conventional imaging methods, medical practitioners and researchers are able to identify the biological pathways in an organism. Based on these pathways and processes, they could administer the required drugs or therapies. Molecular Imaging Molecular imaging is that branch of bioimaging, which studies the function of a particular molecule in a cell or tissue or organism. This branch of bioimaging is not restricted to human beings unlike biomedical imaging. Therefore, the study may also be in respect to viruses and bacteria. Molecular imaging is the study of the molecular structure and the functions or effects of each group forming part of the molecule in the cellular process or metabolic activity of the animal. Biomarkers are used for molecular imaging. Biomarkers or biological indicators highlight the pathways of various cellular and molecular processes. An objective or target action or reaction is identified, and the molecular and cellular processes leading to this objective are examined step by step. This step-by-step process is known as molecular pathway. Molecular imaging records the chemical reactions of biomarkers with other cellular fluids on this path leading to the identified objective. Such stepwise reaction visuals are useful for detecting and treating any diseases. In addition, they are also useful for identifying the course of
  5. 5. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 5 a drug treatment, thereby indicating the possibilities of adverse reactions or inability to reach the target. Molecular probes are also used in molecular imaging. They are made of a group of atoms or molecules that hook to any cell, structure, or molecule, and expose them by exploiting their properties. Optical or fluorescence imaging, single photon emission computed tomography (SPECT), X-ray computed tomography (CT), positron emission tomography (PET), ultrasound, microwave, and magnetic resonance imaging (MRI), are some other standard techniques used in molecular imaging. Each of these techniques has some unique feature, some advantage over the others, and some limitation when compared to the others. Improvements in molecular imaging probes such as positron emission tomography, magnetic resonance imaging, ultrasound imaging techniques, positron emission tomography, and single photon emission computed tomography, etc., coupled with advanced features in equipments and tools allow superimposed viewing of in vivo tomographic imaging of the probes from genetically engineered mice on human pathological nature. Molecular imaging is also useful for quantitative tests, like how much of a drug dosage is required for achieving the target, or how much time is taken for a given reaction. Though such imaging has potential in several areas, presently it is used for understanding the molecular behavior just before the organism starts showing the symptoms of a disease. This understanding would help in early detection of diseases and infections, thereby reducing the need for drastic measures like surgery or stronger doses of drugs. Molecular bioimaging would pave the way to molecular medicines based on human genomes. It gives the visual evidence of enzyme expressions, function of reporter genes and neurotransmitters, and other processes. Segmentation of Bioimaging Exhibit 1. Segmentation of Global Bioimaging Market by Application and Modalities Application Modalities Diagnostic Ultrasound Research and Development CT MRI PET SPECT *Other *Other includes X-Ray, TEM, OCT etc. © RIT, 2013
  6. 6. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 6 Global Market Analysis Global market for Bioimaging is projected to be US$XX.XX billion by 2020 and is estimated at US$ XX.XX billion in 2012 growing at a CAGR of XX.XX % during the analysis period (2005-2020). Exhibit 2. Bioimaging – Global Value Market Estimations & Predictions (2005-2020) in US$ Billion Year Value 2005 XX.XX 2006 XX.XX 2007 XX.XX 2008 XX.XX 2009 XX.XX 2010 XX.XX 2011 XX.XX 2012 XX.XX 2013 XX.XX 2014 XX.XX 2015 XX.XX 2016 XX.XX 2017 XX.XX 2018 XX.XX 2019 XX.XX 2020 XX.XX CAGR% XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion
  7. 7. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 7 Research and Development Worldwide market for Bioimaging application in Research and Development was estimated at US$XX.XX billion in 2012 and is expected to cross US$ XX.XX billion by 2020 growing at a CAGR of XX.XX % during the period 2005-2020. North America is projected to be the largest market with a share of XX.XX % followed by Europe with XX.XX % 2020. Japan is projected to represent the fastest growing market for application of Bioimaging in Research and Development with a CAGR of XX.XX %. Exhibit 3. Bioimaging in Research and Development – Global Value Market Estimations & Predictions (2005 – 2020) by Geographic Regions for North America, Europe, Japan, Asia-Pacific, Latin America and Rest of World (RoW) in US$ Billion Year/Region North America Europe Japan Asia-Pacific Latin America RoW Total 2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion North America Europe Japan Asia-Pacific Latin America RoW
  8. 8. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 8 III. MARKET DYNAMICS MARKET OVERVIEW Bioimaging - A Prominent Advancement in the Field of Biomedical Research The Bioimaging techniques are regarded as the most promising advancements in the field of present day healthcare and biomedical research. This is being recognized as one of the most comprehensive achievement, which has eased the working conditions of the physicians. In the present medical scenario majority of the diseases are being diagnosed and attended using biomedical imaging techniques. This technique requires a good amount of development to understand the basic functions of the organs in the living system. The main aim of the concept of bioimaging is to provide an effectual understanding of the numerous available imaging modalities like X-ray, Commuted Tomography, emission tomography and magnetic resonance imaging. This is done by relating the basic operating principles of these techniques with that of Imaging technique. The intricate cellular and molecular signaling practices undergoing in the development and homeostasis could only be analyzed using complete analysis of the living organism. These requirements necessitate the biomedical research and drug development to possess numerous dynamic processes in cellular physiology, development and disease conditions of living organism by employing bioimaging technologies. Exhibit 4. List of Major Companies In Europe S. No Company Name Country Website 1 Bayer Pharma AG Germany www.bayerpharma.com 2 Bracco SpA Italy www.bracco.com 3 Carl Zeiss SMT AG Germany www.zeiss.com 4 Covidien PLC Ireland www.covidien.com 5 Esaote SpA Italy www.esaote.com 6 FOCUS GmbH Germany www.focus-gmbh.com 7 GE Healthcare UK www.gehealthcare.com 8 Genetix Ltd. UK www.genetix.com 9 Guerbet SA France www.guerbet.com 10 Imix Adr Finland www.imixadr.com 11 Koninklijke Philips Electronics N.V. The Netherlands www.medical.philips.com 12 Swissray Medical AG Switzerland www.swissray.com © RIT, 2013
  9. 9. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 9 Global Market Analysis The global market for Bioimaging is estimated at US$24.6 billion in 2012 and is expected to reach US$37.5 billion by 2020, growing at a CAGR of 7.67%, during the period 2005-2020. North America is estimated as the largest market valued at US$ 10.8 billion in 2012 (market share of 44.35% in 2012) and is projected to touch US$15.5 billion by 2020. Europe represents the second largest market and is projected to exeed US$ 7 billion by 2020, from an estimated value of US$ 4.5 billion in 2012. Japan is estimated as the fastest growing market with a CAGR of 9.17%, during the same analysis period. Asia-Pacific is projected as the second fastest growing segment with a CAGR of 8.93% to reach US$ 4.8 billion by 2020. Exhibit 5. Bioimaging – Global Value Market Estimations & Predictions (2005 – 2020) by Geographic Region for North America, Europe, Japan, Asia-Pacific, Latin America and Rest of World in US$ Billion Year/Region North America Europe Japan Asia-Pacific Latin America RoW Total 2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion North America Europe Japan Asia-Pacific Latin America RoW
  10. 10. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 10 BIOIMAGING – THE OUTLOOK The Biomedical Imaging stream would evolve as a pillar for diagnosis; this further improves other techniques that play a competitive role in imaging. The imaging market is growing day by day, i.e. from US$ XX.XX billion in 2012, it is projected to reach US$XX.XX billion by 2020 with a XX.XX % growth rate hence showing the potentiality of imaging as a research tool in the market. This focus on the medical market gives rise to many innovative tools and business opportunities. There is an adequate need for development of new imaging techniques. With the drastic development in Cell Biology, Biochemistry, and also in computer analysis, use of molecular imaging technologies has increased exponentially in recent years. Major Companies such as GE Healthcare (UK), Bayer Pharma (Germany), Hologic, Siemens Medical (USA), Esaote SpA (Italy), Hitachi, Shimadzu (Japan) hold a major share in the Bioimaging market. Numerous other players share the market. Competition is very high due to the high demand of these products. Advances in image acquisition have led to the expansion of the dimensionality of data sets, especially when data sets include local directional information on fiber orientation or four-dimensional (4-D) blood flow. Such sophisticated analysis cannot be interpreted visually without proper supportive image analysis. The advent of in-vivo molecular imaging modalities such as fluorescence and bioluminescence imaging, which enable the live imaging of gene expression and protein interactions, is also a major trend. Longitudinal image analysis is another major trend that is done to characterize diseases in single patients or patient cohorts. Objective quantitative benchmarking of analysis methods is a strong growth area………
  11. 11. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 11 IV. PRODUCT TECHNOLOGY/RESEARCH It is seen that the potent systems of cellular imaging have been evolved for helping in drug discovery as the physiological environment of an organism or a cell is highly convoluted. With the many detection technologies that are available it is now possible to perform a quantitative analysis of cellular events and also relevant cellular phenotypes are amenable for being better visualized. Presently the process of cellular imaging is helping to amalgamate convoluted biology into screening procedures. This takes care of high- throughput needs and fulfills high-content necessities. Imaging techniques are non-invasive. Most important among them are CT, MRI, and PET scanners, and Sonography. CT is Computed Tomography. SPECT [Single Photon Emission Computer Tomography] is an improved version of it. MRI [Magnetic Resonance Imaging] relies on the phenomenon of NMR [nuclear magnetic resonance]. PET [Positron Emission Tomography] makes use of positron emitting isotopes of oxygen, carbon and fluorine. Sonography involves ultrasounds. Besides these techniques, X-ray and MRS [MR spectroscopy] are also well known imaging techniques. Imaging Techniques Imaging techniques are nowadays extensively employed in disease diagnosis. CT, MRI and PET scanners, and sonography have become common and indispensable medical imaging tools in clinical laboratories and radiology department of hospitals. PET scan has the advantage of providing information on the metabolic status of tissues, which could not be obtained by using CT, MRI or X-ray devices. Sonography is useful to get a picture of tissues and organs of the body. Imaging contrivances like mammography and colonoscopy are meant for detecting cancers in specific organs. PET makes use of positron emitting isotopes which could be tagged to the drug itself to localize its distribution in tissues of interest. This enables direct measurement, making conventional and indirect measurement techniques like blood sample analysis superfluous. Instead, the target tissue, as for example the neuroreceptor sites, could be labeled specifically to the drug of interest. Techniques that facilitate measurement of blood flow, metabolic activities, and function of second messenger are also employed. All these techniques provide valuable information on the physiology, biochemistry and pharmacology of the tissue targeted for investigation. Imaging techniques help the doctors to decide on the course of treatment to be given to the individual patient. MRS and imaging tools such as PET permit quantitative evaluation of brain function. The advantage of using PET has been realized in certain clinical trials in which quantitative measurement of the labeled serotonergic agent crossing the blood-brain barrier could be performed. PET has opened new vistas in research related to treatment of Parkinson’s disease, rheumatoid arthritis, and cancer. Cancer is a major area for the application of imaging techniques. The diagnostic modalities like MRS and PET combined with experimental procedures like molecular imaging help the scientists to comprehend the pathophysiology of a disease, particularly tumor metabolism and tumor-associated angiogenesis. An initiative called ‘Reinventing the Regulation of Cancer Drugs’ proclaimed that methods of cancer treatment would be given approval after verifying their efficacy in bringing about tumor shrinkage.
  12. 12. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 12 Exhibit 6. Therapeutic and Diagnostic Imaging Antibodies – Global Value Market Estimations & Predictions (2005 – 2020) in US$ Billion Year Value 2005 XX.XX 2006 XX.XX 2007 XX.XX 2008 XX.XX 2009 XX.XX 2010 XX.XX 2011 XX.XX 2012 XX.XX 2013 XX.XX 2014 XX.XX 2015 XX.XX 2016 XX.XX 2017 XX.XX 2018 XX.XX 2019 XX.XX 2020 XX.XX CAGR% XX.XX © RIT Figures, 2013 About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion
  13. 13. RITMIR020: Bioimaging – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 13 based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development. Research – As Good as the Methodology is!  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets © COPYRIGHT The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company. DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.

×